Our Research

Current internal cancer research


Implementation of validated blood-based biomarkers in:

  • Improved CRC screening
  • Improved screening for extra-colonic malignancies
  • Early detection of recurrent disease in patients treated for CRC
  • Individualized chemo-/radio-/immunotherapy




  • Early detection of neoplastic diseases—improved survival
  • Detection of benign neoplastic lesions that may be resected/excised—reduction of cancer diagnoses
  • Reduction of unnecessary examinations (colonoscopies/scannings)—improved health economy




Four research tracks




Since 1990 the overall research has been on colorectal cancer and other neoplastic non-bowel lesions with focus on:

  • Tumorigenesis
  • Invasion and metastasis processes
  • Treatment
  • Recurrence
  • Prognosis
  • Prediction
  • Selection
  • Monitoring


Presently achieved overall results

The research has currently identified blood-based biomarkers that may identify subjects with:

  • Colorectal cancer – all stages
  • Adenomas – all categories
  • Extra-colonic malignancies
  • High-risk of developing subsequent malignancy


Background for the current research

Colorectal cancer (CRC= bowel cancer) is an age related disease.
Symptoms with the disease are often not recognized until the late stages of the disease,
where complete cure is hardly achievable.

  • Annually, approximately 2,100 Danes die of the disease—and > 4,250 new diagnoses are established.
    At present, about 22,500 Danes have the diagnosis—50-–55% are estimated to survive > 5 years
  • Bowel cancer is curable in early stages
  • Population screening has been implemented as part of the entire offer of treatment


Current screening in Denmark

  • At present, the screening in Denmark is based on a FIT test (a test for occult blood in feces),
    where a FIT-positive screening-test  will activate an offer of a subsequent colonoscopy
  • The FIT test has a sensitivity of 75% at 90–95% specificity—thus,at present, being the most cost/effective model for the Danish screening
  • The current compliance rate is 64%  (August 2016)
  • Only 48% of those with neoplastic bowel lesions will be identified by FIT screening
  • 52% of those in the screen relevant population with a neoplastic bowel lesion is not identified—mostly due to the lack in screen compliance
  • The first 4 years of The Danish CRC-screening has been a success with findings of many subjects with adenomas (premalignant lesions) or the disease CRC.
    Consequences are that the overall requirement of colonoscopies—screening, diagnostic and adenoma control—
    far exceeds the Danish examination capacity, in total.
    To date, wait time has emerged for all colonoscopies.
    Particularly, the screening-derived colonoscopies cannot be executed within the statutory 14 days.
    Besides, by 2018, the screening interval will be reduced from 4 to just 2 years.



Additional information:

Research Areas     Symposium Aug.2014       
UK _FORSIDE_report_Side_1


Print Friendly, PDF & Email


ColoRectal Cancer Research

Gastroenheden, Hvidovre Hospital

Kettegård Allé 30

2650 Hvidovre

Email: info@colorectalcancer.dk